Decheng Capital LLC
CIK: 0002010850Latest portfolio: $743.4M · Q4 2025
Holdings
19
Total Value
$743.4M
New Positions
0
Closed Positions
4
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | CGONCG ONCOLOGY INC | 6,371,669 | $264.6M | 35.59% | — | |
| 2 | NUVBNuvation Bio Inc. | 25,954,439 | $232.6M | 31.28% | — | |
| 3 | UPBUpstream Bio Inc. | 3,143,078 | $85.3M | 11.48% | -142,215 | |
| 4 | AARDAARDVARK THERAPEUTICS INC | 3,917,299 | $51.4M | 6.92% | — | |
| 5 | LYELLyell Immunopharma, Inc. | 692,050 | $21.3M | 2.87% | +97K | |
| 6 | NAMSNEWAMSTERDAM PHARMA CO NV | 592,057 | $20.8M | 2.79% | -64,994 | |
| 7 | RVMDREVOLUTION MEDICINES INC(NSM) | 200,000 | $15.9M | 2.14% | -10,000 | |
| 8 | RCUSArcus Biosciences, Inc | 541,559 | $12.9M | 1.74% | -6,050 | |
| 9 | ACRSAclaris Therapeutics, Inc. | 4,041,736 | $12.2M | 1.64% | — | |
| 10 | EQEquillium Inc. | 4,447,308 | $6.9M | 0.93% | — | |
| 11 | BYSIBeyondSpring Inc. | 3,800,702 | $6.2M | 0.83% | -485,402 | |
| 12 | CRNXCRINETICS PHARMACEUTICALS IN | 92,700 | $4.3M | 0.58% | -50,300 | |
| 13 | KRYSKRYSTAL BIOTECH INC | 17,300 | $4.3M | 0.57% | -15,000 | |
| 14 | AURAAura Biosciences, Inc. | 360,483 | $2.0M | 0.26% | -155,072 | |
| 15 | ZNTLZentalis Pharmaceuticals Inc. | 1,323,327 | $1.8M | 0.24% | — | |
| 16 | PYXSPyxis Oncology, Inc (formerly Apexigen) | 326,810 | $375K | 0.05% | — | |
| 17 | FDMT4D MOLECULAR THERAPEUTICS IN | 44,311 | $332K | 0.04% | -48,437 | |
| 18 | NUVB/WSNuvation Bio Inc. | 646,057 | $213K | 0.03% | — | |
| 19 | RZLTREZOLUTE INC | 59,900 | $141K | 0.02% | — |
Quarterly Changes
New Positions
No new positions this quarter
Sector Breakdown
Healthcare0.0% ($2.6455123255185335e+70T)
Unknown0.0% ($213K)
Filing History
Fund Information
Decheng Capital LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $743.4M across 19 holdings. The largest position is CG ONCOLOGY INC (CGON), representing 35.6% of the portfolio. Compared to the previous quarter, the fund opened 0 new positions and closed 4 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.